Oncology

Investigation of Low-dose Abdominal Radiation Therapy for the Treatment of Feline Small Cell Gastrointestinal Lymphoma.

Title: Investigation of Low-dose Abdominal Radiation Therapy for the Treatment of Feline Small Cell Gastrointestinal Lymphoma.
Contact Person: Please contact Dr. Michael Deveau, DVM, MS, directly with any questions regarding this trial and how to refer patients for consideration. Email is the preferred route of contact to ensure the quickest turnaround.
mdeveau@cvm.tamu.edu | (979) 845-2351
Species: Feline
Inclusion Criteria and General Background Information:
  • Are greater than 1 year of age
  • Are any breed, size, sex, and weigh at least 2 Kg (4.5 lbs)
  • Confirmed histopathologic diagnosis of small cell gastrointestinal lymphoma.
  • No other series co-morbidities or other neoplasia (advanced heart disease, advanced kidney disease, etc)
  • Have no evidence of spread of the tumor outside the intestines, liver, spleen or lymph nodes within the abdomen at enrollment
  • Be deemed a good anesthetic candidate for 2 anesthesia periods, 24 hours apart
  • Must be on chlorambucil chemotherapy for > 1 month < 6 months prior to radiation therapy
  • Must be deemed during staging to be in a complete or partial remission based on intestinal infiltration.

The purpose of this clinical trial is to determine if the addition of radiation therapy to the intestines is effective at delaying the recurrence of lymphoma within the intestines when used in addition to the standard of care treatment chemotherapy.

The study will include a pre-radiation workup (CBC, Chemistry, urinalysis, three-view thoracic radiographs, and abdominal ultrasound), one CT scan for radiation therapy planning (done prior to and under the same anesthesia as the administration of the first radiation dose) and two episodes of radiation under generalized anesthesia administered 24 hours apart. Follow up rechecks at Texas A&M Small Animal Teaching Hospital at 2 weeks, 1 month, and every 3 months after completion of radiation therapy until relapse of disease or discontinued by investigators.

Exclusion Criteria:
Owner Commitments: The owner of any participating animal is financially responsible for costs associated with the treatment of complications or accidental injuries associated with this study. Should the study patient experience an unanticipated side effect directly associated (as determined by a review committee of oncologists at TAMU) with radiation therapy, a stipend of up to $1000 dollars for treatment management will be provided.
Financial Incentives: The owner is responsible for pre-enrollment diagnostics to meet eligibility criteria (including but not limited to a complete blood count, chemistry panel, urinalysis, chest x-rays and aspirate or biopsy of the tumor), abdominal ultrasound, and the cost of standard of care chemotherapy. Should the patient be found eligible the owner will be reimbursed:

  • the cost of the pre-radiation therapy CBC, chemistry, urinalysis chest radiographs, and abdominal ultrasound costs
  • the cost of radiation therapy (including anesthesia and associated hospitalization charges) will be covered by the study.
  • the subsequent follow-up recheck exams after completion of radiation therapy until relapse of disease or discontinued by investigators will be covered up to $250 per visit.

Use of a novel agent, RTI, to extend the disease free interval in dogs with lymphoma.

Title: Use of a novel agent, RTI, to extend the disease free interval in dogs with lymphoma.
Contact Person: Heather Wilson-Robles, DVM, DACVIM (Oncology)
oncology@cvm.tamu.edu | (979) 845-2351
Species: Canines
Inclusion Criteria and General Background Information: Must be a canine patient newly diagnosed with lymphoma, weigh at least 10 lbs, and is in good general health (outside of lymphoma diagnosis). Must be Stage 4 or less, substage a.

Lymphoma is a common tumor of the dog. The type of lymphoma that dogs get is very aggressive and >90% of them will die of the disease within 2 years even with aggressive therapy. The goal of this project is to see if a drug, RTI, originally used to treat tuberculosis in humans, can be used to create enhanced sensitivity of tumor cells to standard chemotherapy, i.e. make chemotherapy work better for longer.

Exclusion Criteria: Canine individuals will not be eligible if they have ever received any form of other chemotherapy, received investigational therapy or radiation therapy. Canine patient must not have been given steroids for more than 14 days before enrollment.
Owner Commitments: Some staging expenses will be paid for by the owner including blood work, diagnosis of lymphoma and x-rays of the chest. The staging test will be determined by the senior clinician. In addition, any costs associated with the treatment of complications or accidental injuries associated with this study will also be covered at the owner’s expense. This will require weekly visits to the Texas A&M Veterinary Medical Teaching Hospital (VMTH) for the entirety of the CHOP treatment (19 weeks) as well as monthly follow-ups for at least 8 months after completing chemotherapy.
Financial Incentives: Enrolled canine patients are eligible to receive some financial help with complete staging tests (study will pay for an abdominal ultrasound, bone marrow aspirate and immunophenotyping of the cancer), the experimental drug for no cost and up to $3,000 towards CHOP chemotherapy expenses.